ROCHESTER (WWJ) -- OptimizeRx Corp. (OTCQB: OPRX) Friday announced the resignation of the company's CEO, Shadron L. Stastney.
The statement cited "personal reasons" for the resignation. No details were given.
OptimizeRx in a statement said it accepted the resignation, and said Stastney will be retained "on a limited basis for advisory work through the end of the year to help the transition with several ongoing projects."
"We appreciate all the valuable contributions made by Mr. Stastney, and we wish him the best of luck in his future endeavors," the company's co-chairman and founder David Harrell said in a statement. "The company has initiated a search for an executive with proven leadership qualities and experience in the pharmaceutical industry."
Harrell said he would reassume the title of board chairman, and the company is also considering adding additional staff to handle its diversification into additional services.
Last week the company announced a strategic planning service called OptimizEHR, designed to help pharmaceutical manufacturers to develop robust brand based digital offerings for the fast-growing electronic health records software industry.
OptimizeRx develops technology to help patients better afford medicine and other healthcare products, and to help them more effectively comply with treatment plans.
More at www.optimizerxcorp.com.
for more features.